Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
UCB Biopharma SRL
Kristian Reich; Kim A Papp; Andrew Blauvelt; Richard G Langley; April Armstrong; Richard B Warren; Kenneth B Gordon; Joseph F Merola; Yukari Okubo; Cynthia Madden; Maggie Wang; Christopher Cioffi; Veerle Vanvoorden; Mark Lebwohl